Daiichi Sankyo-Merck’s Cancer Drug Meets Main Goal in Late-stage Trial

(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in some patients with a type of lung cancer.
The drug helped patients live significantly longer without their cancer progressing, compared with patients who were treated with chemotherapy, the companies said.
The drug belongs to a class of treatments called antibody-drug conjugates, which have often been described as “guided-missile” cancer drugs.
Patritumab deruxtecan was tested in patients with non-small cell lung cancer who had a gene mutation called EGFR. Non-small cell lung cancer is the most common form of lung cancer.
The study focused on patients who had previously received treatment with a class of drugs known as tyrosine kinase inhibitors.
(Reporting by Sriparna Roy and Kashish Tandon in Bengaluru; Editing by Tasim Zahid)
 
Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.